Jianbo Wu1, Tammy L Strawn2, Mao Luo2, Liqun Wang2, Rong Li2, Meiping Ren2, Jiyi Xia2, Zhuo Zhang2, Weizhong Ma2, Tingting Luo2, Daniel A Lawrence2, William P Fay2. 1. From the Departments of Internal Medicine and Medical Pharmacology and Physiology (J.W., T.L.S., M.L., W.P.F.), the Research Service, Harry S. Truman Memorial Veterans Hospital (W.P.F.), University of Missouri School of Medicine, Columbia; the Drug Discovery Research Center, Luzhou Medical College, Luzhou, Sichuan, China (J.W., M.L., L.W., R.L., M.R., J.X., Z.Z., W.M., T.L.); and the Department of Internal Medicine, University of Michigan Medical School, Ann Arbor (D.A.L.). wuji@missouri.edu. 2. From the Departments of Internal Medicine and Medical Pharmacology and Physiology (J.W., T.L.S., M.L., W.P.F.), the Research Service, Harry S. Truman Memorial Veterans Hospital (W.P.F.), University of Missouri School of Medicine, Columbia; the Drug Discovery Research Center, Luzhou Medical College, Luzhou, Sichuan, China (J.W., M.L., L.W., R.L., M.R., J.X., Z.Z., W.M., T.L.); and the Department of Internal Medicine, University of Michigan Medical School, Ann Arbor (D.A.L.).
Abstract
OBJECTIVE: Plasminogen activator inhibitor-1 (PAI-1) regulates angiogenesis via effects on extracellular matrix proteolysis and cell adhesion. However, no previous study has implicated PAI-1 in controlling vascular endothelial growth factor (VEGF) signaling. We tested the hypothesis that PAI-1 downregulates VEGF receptor-2 (VEGFR-2) activation by inhibiting a vitronectin-dependent cooperative binding interaction between VEGFR-2 and αVβ3. APPROACH AND RESULTS: We studied effects of PAI-1 on VEGF signaling in human umbilical vein endothelial cells. PAI-1 inhibited VEGF-induced phosphorylation of VEGFR-2 in human umbilical vein endothelial cells grown on vitronectin, but not on fibronectin or collagen. PAI-1 inhibited the binding of VEGFR-2 to β3 integrin, VEGFR-2 endocytosis, and intracellular signaling pathways downstream of VEGFR-2. The anti-VEGF effect of PAI-1 was mediated by 2 distinct pathways, one requiring binding to vitronectin and another requiring binding to very low-density lipoprotein receptor. PAI-1 inhibited VEGF-induced angiogenesis in vitro and in vivo, and pharmacological inhibition of PAI-1 promoted collateral arteriole development and recovery of hindlimb perfusion after femoral artery interruption. CONCLUSIONS: PAI-1 inhibits activation of VEGFR-2 by VEGF by disrupting a vitronectin-dependent proangiogenic binding interaction involving αVβ3 and VEGFR-2. These results broaden our understanding of the roles of PAI-1, vitronectin, and endocytic receptors in regulating VEGFR-2 activation and suggest novel therapeutic strategies for regulating VEGF signaling.
OBJECTIVE:Plasminogen activator inhibitor-1 (PAI-1) regulates angiogenesis via effects on extracellular matrix proteolysis and cell adhesion. However, no previous study has implicated PAI-1 in controlling vascular endothelial growth factor (VEGF) signaling. We tested the hypothesis that PAI-1 downregulates VEGF receptor-2 (VEGFR-2) activation by inhibiting a vitronectin-dependent cooperative binding interaction between VEGFR-2 and αVβ3. APPROACH AND RESULTS: We studied effects of PAI-1 on VEGF signaling in human umbilical vein endothelial cells. PAI-1 inhibited VEGF-induced phosphorylation of VEGFR-2 in human umbilical vein endothelial cells grown on vitronectin, but not on fibronectin or collagen. PAI-1 inhibited the binding of VEGFR-2 to β3 integrin, VEGFR-2 endocytosis, and intracellular signaling pathways downstream of VEGFR-2. The anti-VEGF effect of PAI-1 was mediated by 2 distinct pathways, one requiring binding to vitronectin and another requiring binding to very low-density lipoprotein receptor. PAI-1 inhibited VEGF-induced angiogenesis in vitro and in vivo, and pharmacological inhibition of PAI-1 promoted collateral arteriole development and recovery of hindlimb perfusion after femoral artery interruption. CONCLUSIONS:PAI-1 inhibits activation of VEGFR-2 by VEGF by disrupting a vitronectin-dependent proangiogenic binding interaction involving αVβ3 and VEGFR-2. These results broaden our understanding of the roles of PAI-1, vitronectin, and endocytic receptors in regulating VEGFR-2 activation and suggest novel therapeutic strategies for regulating VEGF signaling.
Authors: P M Rettenberger; K Oka; L Ellgaard; H H Petersen; A Christensen; P M Martensen; D Monard; M Etzerodt; L Chan; P A Andreasen Journal: J Biol Chem Date: 1999-03-26 Impact factor: 5.157
Authors: Ganapati H Mahabeleshwar; Juhua Chen; Weiyi Feng; Payaningal R Somanath; Olga V Razorenova; Tatiana V Byzova Journal: Cell Cycle Date: 2007-11-01 Impact factor: 4.534
Authors: Masanori Nakayama; Akiko Nakayama; Max van Lessen; Hiroyuki Yamamoto; Sarah Hoffmann; Hannes C A Drexler; Norimichi Itoh; Tomonori Hirose; Georg Breier; Dietmar Vestweber; Jonathan A Cooper; Shigeo Ohno; Kozo Kaibuchi; Ralf H Adams Journal: Nat Cell Biol Date: 2013-01-27 Impact factor: 28.824
Authors: Evandro M Neto-Neves; Mary B Brown; Maria V Zaretskaia; Samin Rezania; Adam G Goodwill; Brian P McCarthy; Scott A Persohn; Paul R Territo; Jeffrey A Kline Journal: Am J Pathol Date: 2017-02-07 Impact factor: 4.307
Authors: Yared Tekabe; Qing Li; Geping Zhang; Jordan Johnson; Ann Marie Schmidt; Marina Backer; Joseph Backer; Lynne L Johnson Journal: Mol Imaging Biol Date: 2018-12 Impact factor: 3.488
Authors: A G Kutikhin; D K Shishkova; E A Velikanova; M Yu Sinitsky; A V Sinitskaya; V E Markova Journal: J Evol Biochem Physiol Date: 2022-06-29 Impact factor: 1.621
Authors: Daniele Chaves-Moreira; Marilyn A Mitchell; Cristina Arruza; Priyanka Rawat; Simone Sidoli; Robbin Nameki; Jessica Reddy; Rosario I Corona; Lena K Afeyan; Isaac A Klein; Sisi Ma; Boris Winterhoff; Gottfried E Konecny; Benjamin A Garcia; Donita C Brady; Kate Lawrenson; Patrice J Morin; Ronny Drapkin Journal: Sci Signal Date: 2022-04-05 Impact factor: 9.517
Authors: Takerra K Johnson; Lina Zhao; Dihan Zhu; Yang Wang; Yan Xiao; Babayewa Oguljahan; Xueying Zhao; Ward G Kirlin; Liya Yin; William M Chilian; Dong Liu Journal: Am J Physiol Heart Circ Physiol Date: 2019-08-16 Impact factor: 4.733